We are live on ! Find out more
NAGE

Niagen Bioscience
NAGE

61 hedge funds and large institutions have $32.7M invested in Niagen Bioscience in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

0.01% less ownership

Funds ownership: 17.33% → 17.32% (-0.01%)

5% less funds holding

Funds holding: 64 → 61 (-3)

20% less capital invested

Capital invested by funds: $40.9M → $32.7M (-$8.12M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
61
Holders Change
-3
Holders Change %
-4.69%
% of All Funds
1.35%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
16
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$84.8K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$78K
3
BFM
Boothbay Fund Management
New York
+$60.9K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$60.3K
5
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$58.6K

Top Sellers

Rank Fund Capital Flow
1
OC
Oppenheimer & Co
New York
-$148K
2
Deutsche Bank
Deutsche Bank
Germany
-$128K
3
ARTA
A.R.T. Advisors
New York
-$93K
4
Jane Street
Jane Street
New York
-$90K
5
WSTAM
Wilbanks Smith & Thomas Asset Management
Virginia
-$86K

NAGE Hedge Fund Activity: Q4 2018 in Review

61 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2018, worth a combined $32.7M — down 20% from $40.9M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NAGE and 7 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 16 added.

The largest buyer was Bank of New York Mellon, adding an estimated $84.8K. The largest seller was Oppenheimer & Co, cutting an estimated $148K.

  • 61 institutional investors held Niagen Bioscience (NAGE) as of Q4 2018, down from 64 in Q3 2018.
  • Funds reported $32.7M of Niagen Bioscience stock for Q4 2018, down 20% quarter-over-quarter.
  • 7 funds opened new Niagen Bioscience positions in Q4 2018 and 10 closed out, a net change of -3 holders.
  • The largest Niagen Bioscience buyer in Q4 2018 was Bank of New York Mellon, an estimated $84.8K added.
  • The largest Niagen Bioscience seller in Q4 2018 was Oppenheimer & Co, an estimated $148K sold.

Based on aggregated 13F filings for Q4 2018.